abnorm process pro-igf-ii patient hepatoma hepat viru antibody-posit asymptomat individu hepatoma common malign countri high preval hepat viru infect tumor sever persist hypoglycemia possibl relationship product insulin-lik growth factor II igf-ii tumor develop hypoglycemia mean igf-ii concentr patient hypoglycemia patient euglycemia SE vs micrograms/l serum igf-i suppress patient hypoglycemia micrograms/l patient euglycemia micrograms/l increas percentag igf-ii serum patient hypoglycemia tumor present pro-igf-ii big igf-ii sera patient hypoglycemia patient euglycemia hepatoma acid bio-gel column igf-ii sera patient hypoglycemia present big igf-ii patient euglycemia hepatoma differ normal control healthi control subject hepat viru posit percentag big igf-ii abnorm process pro-igf-ii subtl chang liver function infect subject increas big igf-ii risk develop hepatoma conclus mark suppress igf-i sera patient hepatoma hypoglycemia 